Применение карведилола у больных с метаболическим синдромом
Аннотация
Об авторах
В. Б. МычкаРоссия
И. Е. Чазова
Россия
Список литературы
1. Fogari R, Zoppi A, Corradi L et al. beta - blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999;534-9
2. Fogari R et al. beta - blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (Suppl 5): S76
3. Sponer G, Bartsch W, Strein K, Muller-Beckmann B, Bohm E. Pharmacological profile of carvedilol as a beta - blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987; 9(3):317-327
4. Weber K, Bohmeke T, van der Does R, Taylor S.H. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996;10(2):113-117
5. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non - insulin - dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126(12):955-959
6. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang P.D. A double - blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993; 45(2):95-100
7. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin H.J, Dietze G.J. Differential effect of chronic treatment with two beta - blocking agents on insulin sensitivity: the carvedilol - metoprolol study. J Hypertens 1996;14(4):489-494 Lysko P.G, Webb C.L, Gu J.L, Ohlstein E.H, Ruffolo R.R.Jr, Yue T.L. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000;36(2):277-281
8. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta - adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996;27(4):532-538
9. Ohlstein E.H, Douglas S.A, Sung C.P, Yue T.L, Louden C, Arleth A, Poste G, Ruffolo R.R Jr, Feuerstein G.Z. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90(13):6189-6193
10. Yue T.L. Antioxidant action of carvedilol. A potential role in treatment of heart failure. Heart Failure Reviews 1999;4:39-51
11. Stienen U, Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a meta - analysis approach. Clin Invest 1992;70(Suppl 1):S65-S72
12. Goette D. Anwendungsbeobachtungen im Spannungsfeld von Wissenschaft und Marketing. Dtsch Med Wschr 2003;128:49-50
13. G.E. Shuetze, G.V. Sabin, I. Janitzki, A. Scherhag. Treatment of essential hypertension with Carvedilol: Results of the open - lable prospective trial in more then 10 000 patients. Perfusion 2003; 16:424-429
14. George L. Bakris, Vivian Fonseca, Richard E. Katholi at al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. A Randomized Controlled Trial. JAMA, November 10, 2004-Vol. 292, No. 18
Рецензия
Для цитирования:
Мычка В.Б., Чазова И.Е. Применение карведилола у больных с метаболическим синдромом. Системные гипертензии. 2005;(2):22-26.
Послать статью по эл. почте 